Literature DB >> 18579551

Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD.

D M Mannino1, D Thorn, A Swensen, F Holguin.   

Abstract

Chronic obstructive pulmonary disease (COPD) is associated with important chronic comorbid diseases, including cardiovascular disease, diabetes and hypertension. The present study analysed data from 20,296 subjects aged > or =45 yrs at baseline in the Atherosclerosis Risk in Communities Study (ARIC) and the Cardiovascular Health Study (CHS). The sample was stratified based on baseline lung function data, according to modified Global Initiative for Obstructive Lung Disease (GOLD) criteria. Comorbid disease at baseline and death and hospitalisations over a 5-yr follow-up were then searched for. Lung function impairment was found to be associated with more comorbid disease. In logistic regression models adjusting for age, sex, race, smoking, body mass index and education, subjects with GOLD stage 3 or 4 COPD had a higher prevalence of diabetes (odds ratio (OR) 1.5, 95% confidence interval (CI) 1.1-1.9), hypertension (OR 1.6, 95% CI 1.3-1.9) and cardiovascular disease (OR 2.4, 95% CI 1.9-3.0). Comorbid disease was associated with a higher risk of hospitalisation and mortality that was worse in people with impaired lung function. Lung function impairment is associated with a higher risk of comorbid disease, which contributes to a higher risk of adverse outcomes of mortality and hospitalisations.

Entities:  

Mesh:

Year:  2008        PMID: 18579551     DOI: 10.1183/09031936.00012408

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  316 in total

1.  Prevalence and risk factors of aortic aneurysm in patients with chronic obstructive pulmonary disease.

Authors:  Katsutoshi Ando; Norihiro Kaneko; Tokuhide Doi; Masahiro Aoshima; Kazuhisa Takahashi
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

2.  James Mackenzie Lecture 2011: multimorbidity, goal-oriented care, and equity.

Authors:  Jan De Maeseneer; Pauline Boeckxstaens
Journal:  Br J Gen Pract       Date:  2012-07       Impact factor: 5.386

3.  Corrination of a GLP-1 Receptor Agonist for Glycemic Control without Emesis.

Authors:  Tito Borner; Jayme L Workinger; Ian C Tinsley; Samantha M Fortin; Lauren M Stein; Oleg G Chepurny; George G Holz; Aleksandra J Wierzba; Dorota Gryko; Ebba Nexø; Evan D Shaulson; Ankur Bamezai; Valentina A Rodriguez Da Silva; Bart C De Jonghe; Matthew R Hayes; Robert P Doyle
Journal:  Cell Rep       Date:  2020-06-16       Impact factor: 9.423

Review 4.  Systematic review of humanistic and economic burden of symptomatic chronic obstructive pulmonary disease.

Authors:  Kunal Srivastava; Deepika Thakur; Sheetal Sharma; Yogesh Suresh Punekar
Journal:  Pharmacoeconomics       Date:  2015-05       Impact factor: 4.981

Review 5.  Optimum bronchodilator combinations in chronic obstructive pulmonary disease: what is the current evidence?

Authors:  Matthew C Miles; James F Donohue; Jill A Ohar
Journal:  Drugs       Date:  2012-02-12       Impact factor: 9.546

Review 6.  Should mild COPD be treated? Evidence for early pharmacological intervention.

Authors:  Amany F Elbehairy; Katherine A Webb; J Alberto Neder; J Alberto Neder; Denis E O'Donnell
Journal:  Drugs       Date:  2013-12       Impact factor: 9.546

7.  Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendations.

Authors:  Dheeraj Gupta; Ritesh Agarwal; Ashutosh Nath Aggarwal; V N Maturu; Sahajal Dhooria; K T Prasad; Inderpaul S Sehgal; Lakshmikant B Yenge; Aditya Jindal; Navneet Singh; A G Ghoshal; G C Khilnani; J K Samaria; S N Gaur; D Behera
Journal:  Lung India       Date:  2013-07

8.  Chronic obstructive pulmonary disease: an update of treatment related to frequently associated comorbidities.

Authors:  Nicola J Sinden; Robert A Stockley
Journal:  Ther Adv Chronic Dis       Date:  2010-03       Impact factor: 5.091

Review 9.  Once-daily long-acting beta₂-agonists/inhaled corticosteroids combined inhalers versus inhaled long-acting muscarinic antagonists for people with chronic obstructive pulmonary disease.

Authors:  Agnieszka Sliwka; Milosz Jankowski; Iwona Gross-Sondej; Monika Storman; Roman Nowobilski; Malgorzata M Bala
Journal:  Cochrane Database Syst Rev       Date:  2018-08-24

10.  Firing probability and mean firing rates of human muscle vasoconstrictor neurones are elevated during chronic asphyxia.

Authors:  Cynthia Ashley; Danielle Burton; Yrsa B Sverrisdottir; Mikael Sander; David K McKenzie; Vaughan G Macefield
Journal:  J Physiol       Date:  2010-01-05       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.